Cancer Fund Impact Investments
CANCER FUND is pleased to announce its investment in NXgenPort, an early-stage company developing technology to advance remote monitoring of cancer patients’ health. This marks Cancer Fund I’s seventh investment and reflects its dedication to fostering impactful innovations in oncology.
NXgenPort is designing an implantable smart port that integrates conventional vascular access with technology intended to provide daily, in vivo monitoring of key patient metrics, such as changes in blood cell counts, body temperature and pulse. By utilizing light-scattering technology, NXgenPort’s solution seeks to enable regular data collection that can be synced to a cloud-based dashboard for physician access. This system aims to address gaps in care by supporting earlier detection of potential complications, such as infections, and helping avoid delays in treatment, thus improving outcomes and reducing costs.
